Anti-Human IL 12/23 (Briakinumab) Dylight® 488
£304.69
Anti-Human IL 12/23 (Briakinumab) Dylight® 488 (LT511-100ug)
Product
| Cat # LT511-100ug | Size 100 µg |
Price
£304.69
|
Qty
|
Description
Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT511 |
| Product Size | 100 µg |
| Concentration | 0.2 mg/ml |
| Formulation | This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Clone | ABT-874 |
| Target | IL-12/IL-23 p40 |
| Applications | FA, FC, IF |
| Antigen | IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes. |
| Storage | This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. |
| Protein | IL-12/IL-23 p40 |